Category Archives: News

Clarity reaches 50% recruitment milestone for DISCO neuroendocrine tumour diagnostic Phase II trial

Sydney, Australia 16 February 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its Phase II diagnostic 64Cu SARTATE trial (DISCO NCT044383041) for patients with known or suspected neuroendocrine tumours (NETs) has reached the…

PROPELLER Trial Results – SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer

Sydney, Australia 14 February 2023 Highlights PROPELLER trial achieved all primary and secondary objectives 64Cu SAR-bisPSMA was safe and well tolerated by trial participants Uptake of Clarity’s 64Cu SAR-bisPSMA in cancer lesions is higher compared to the approved standard-of-care for prostate cancer imaging in Australia and the US, 68Ga PSMA-11 Greater uptake into cancer lesions…

Clarity confirms no supply interruptions to its ongoing clinical trials programs

Sydney, Australia 2 March 2023   Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, notes the recent supply interruption for Novartis’ Pluvicto™ radiotherapy to patients1-2 and confirms Clarity’s Targeted Copper Theranostics (TCTs) products and clinical development programs are…

Changes to Clarity’s Board of Directors

Sydney, Australia 1 February 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that Cheryl Maley has joined Clarity’s Board of Directors as a Non-Executive Director. Dr Gillies O’Bryan-Tear has resigned from the…

Positive topline results from Clarity’s PROPELLER SAR-bisPSMA prostate cancer diagnostic trial

Sydney, Australia 14 December 2022 Highlights Clarity’s diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER meets all primary and secondary objectives 64Cu SAR-bisPSMA is safe and well tolerated in trial participants 64Cu SAR-bisPSMA is shown to be efficacious in the detection of primary prostate cancer A dose of 200 megabecquerels (MBq) of 64Cu SAR-bisPSMA was determined…

IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer

Sydney, Australia 21 November 2022 Highlights Clarity’s fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR Bombesin are now under IND for US clinical…

50% recruitment milestone reached for Phase II BOP prostate cancer trial

Sydney, Australia 2 November 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the Phase II diagnostic 64Cu SAR-Bombesin trial (BOP) for patients with prostate cancer has reached the fifty percent recruitment milestone, with 15…

50% recruitment milestone reached for COBRA prostate cancer trial in the US

Sydney, Australia 27 October 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT052491271) for patients with prostate cancer has reached the fifty percent recruitment milestone, with 25 out…

First patient treated in Clarity’s therapeutic prostate cancer trial

Sydney, Australia 7 October 2022 Highlights Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)1 investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) Data from the initial dosimetry phase with 64Cu SAR-bisPSMA was assessed by the Safety Review Committee…

First participant imaged in Phase II SAR-Bombesin prostate cancer trial in the US

Sydney, Australia 6 October 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has successfully imaged its first participant in the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative…